NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cyclerion Therapeutics, Inc. CYCN
8 fiscal years on record · USD · FY2025 reported · SEC filings only
$-3.5M
Growth
USD 2.1M
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 2.1 · Net income -3.5
Compound annual growth
Revenue compounded at −2.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−170 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -239.8% · Net -170.1%
ROE
FY2025 · ROE -39.3%
Each USD of equity lost 39 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | · | · | · | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 |
| EPS, diluted $ | −1.11 | −1.21 | −2.25 | −20.28 | −1.32 | −2.56 | −4.49 | −4.21 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −39.3 | −30.4 | −48.4 | −150.2 | −95.9 | −99.0 | −281.9 | · |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.03 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 44 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inMassachusetts
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2018